J
Joseph J. Eron
Researcher at University of North Carolina at Chapel Hill
Publications - 569
Citations - 49427
Joseph J. Eron is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 99, co-authored 511 publications receiving 44857 citations. Previous affiliations of Joseph J. Eron include Duke University.
Papers
More filters
Journal ArticleDOI
HIV Antigens Can Induce TGF-β1-Producing Immunoregulatory CD8+ T Cells
Mohammed L. Garba,Christopher D. Pilcher,Andrea L. Bingham,Joseph J. Eron,Jeffrey A. Frelinger +4 more
TL;DR: It is reported that ∼25% of HIV+ donors produced TGF-β1 in response to stimulation with HIV proteins or peptides, which was sufficient to significantly reduce the IFN-γ response of CD8+ cells to both HIV and vaccinia virus proteins.
Journal ArticleDOI
Short-Term Safety and Antiretroviral Activity of T-1249, a Second-Generation Fusion Inhibitor of HIV
Joseph J. Eron,Roy M. Gulick,John Bartlett,Thomas C. Merigan,Roberto C. Arduino,J. Michael Kilby,Bienvenido G. Yangco,Adriann Diers,Claude Drobnes,Ralph DeMasi,Michael E. Greenberg,Thomas E. Melby,Claire Raskino,Pam Rusnak,Ying Zhang,Rebecca Spence,G. Diego Miralles +16 more
TL;DR: Results indicate that T-1249 is a potent new therapeutic agent for HIV-1 infection and no dose-limiting toxicity was identified.
Journal ArticleDOI
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Mary Albrecht,Ronald J. Bosch,Scott M. Hammer,Song-Heng Liou,Harold A. Kessler,Michael F. Para,Joseph J. Eron,Hernan Valdez,Marjorie Dehlinger,David Katzenstein +9 more
TL;DR: In HIV-infected patients previously treated with nucleosid analogues, treatment with nelfinavir plus efavirenz and at least one new nucleoside analogue achieves a higher rate of viral suppression than do regimens with nucleOSide analogues and nELFinavir or efvirenz alone.
Journal ArticleDOI
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
Thomas B. Campbell,Laura M. Smeaton,N. Kumarasamy,Timothy P. Flanigan,Karin L. Klingman,Cynthia Firnhaber,Beatriz Grinsztejn,Mina C. Hosseinipour,Johnstone Kumwenda,Umesh G. Lalloo,Cynthia Riviere,Jorge Sanchez,Marineide Gonçalves de Melo,Khuanchai Supparatpinyo,Srikanth Tripathy,Ana Martinez,Apsara Nair,Ann Walawander,Laura Moran,Yun Chen,Wendy Snowden,James F. Rooney,Jonathan Uy,Robert T. Schooley,Victor De Gruttola,James Hakim,Edith Swann,Ronald L. Barnett,Barbara Brizz,Yvette Delph,Nikki Gettinger,Ronald T. Mitsuyasu,Susan H. Eshleman,Steven A. Safren,Susan A. Fiscus,Adriana Andrade,David W. Haas,Farida Amod,Vladimir Berthaud,Robert C. Bollinger,Yvonne J. Bryson,David D. Celentano,David Chilongozi,Myron S. Cohen,Ann C. Collier,Judith S. Currier,Susan Cu-Uvin,Joseph J. Eron,Charles Flexner,Joel E. Gallant,Roy M. Gulick,Scott M. Hammer,Irving F. Hoffman,Peter N. Kazembe,Newton Kumwenda,Javier R. Lama,Jody Lawrence,Chiedza Maponga,Francis Martinson,Kenneth H. Mayer,Karin Nielsen,Richard B. Pendame,Bharat Ramratnam,Ian Sanne,Patrice Severe,Thira Sirisanthana,Suniti Solomon,Steve Tabet,Taha E. Taha,Charles van der Horst,Christine Wanke,Joan Gormley,Cheryl Marcus,Beverly Putnam,Smanga Ntshele,Edde Loeliger,Keith A. Pappa,Nancy Webb,David Shugarts,Mark A. Winters,Renard S. Descallar,Joseph Steele,Michael Wulfsohn,Farideh Said,Yue Chen,John Martin,Norbert Bischofberger,Andrew K. Cheng,Howard Jaffe,Jabin Sharma,Selvamuthu Poongulali,Sandra W. Cardoso,Deise Lucia Faria,Sima Berendes,Kelly Burke,Rosie Mngqibisa,Cecilia Kanyama,Virginia Kayoyo,Wadzanai Samaneka,Anthony Chisada,Sharla Faesen,Suwat Chariyalertsak,Breno Santos,Rita Alves Lira,Anjali A. Joglekar,Alberto La Rosa,Rosa Infante,Mamta K. Jain,T. Petersen,Sheela Godbole,Sampada Dhayarkar,Judith Feinberg,Jenifer Baer,Richard B. Pollard,David M. Asmuth,Raman R. Gangakhedkar,Asmita Gaikwad,M. Graham Ray,Cathi Basler,Michael F. Para,Kathy J. Watson,Babafemi Taiwo,Donna V. McGregor,Henry H. Balfour,Beth D. Mullan,Ge Youl Kim,Michael K. Klebert,Gary M. Cox,Martha Silberman,Donna Mildvan,Manuel Revuelta,Karen T. Tashima,Helen Patterson,P. Jan Geiseler,Bartolo Santos,Eric S. Daar,Ruben Lopez,Laurie Frarey,David Currin,David H. Haas,Vicki L. Bailey,Pablo Tebas,Larisa Zifchak,Jolene Noel-Connor,Madeline Torres,Beverly E. Sha,Janice M. Fritsche,Michelle S. Cespedes,Janet Forcht,William A. O'Brien,Cheryl Mogridge,Christine Hurley,Roberto Corales,Maria Palmer,Mary Adams,Amneris E. Luque,Luis Lopez-Detres,Todd Stroberg +157 more
TL;DR: Findings of a randomized trial conducted in multiple countries regarding the efficacy of antiretroviral regimens with simplified dosing with positive results are reported.
Journal ArticleDOI
Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi
John R. Dyer,Joseph J. Eron,Irving F. Hoffman,Peter N. Kazembe,Pietro Vernazza,Eniffa Nkata,Celine Costello Daly,Susan A. Fiscus,Myron S. Cohen +8 more
TL;DR: Increased HIV-1 in semen was demonstrated in some men with GUD; such an increase could lead to increased transmission, thus complicating interpretation of the role of the genital ulcer itself in the infectiousness of HIV.